Skip to main content

Intestinal ischemia and reperfusion: beneficial effects of a platelet activating factor antagonist

Gut barrier dysfunction in conditions associated with intestinal ischemia and reperfusion (I/R) might contribute to the further development of multiple organ dysfunction. The present study evaluates the effects of platelet activating factor (PAF) antagonist in intestinal I/R injury.


Intestinal ischemia was induced by clamping of the superior mesenteric artery for 40 min followed by 12 h reperfusion. 15 min after the end of ischemia, the rats received intraperitoneal injections of saline or the PAF antagonist lexipafant (5 mg/kg), repeated after 6 h in the groups subjected to 12 h reperfusion. Myeloperoxidase (MPO) content in the small intestine, serum levels of interleukines-1 and 6, plasma protease inhibitors and intestinal endothelial and epithelial permeability were assesed.


Intestinal I/R resulted in intestinal barrier dysfunction with pronounced plasma leakage to the intestinal lumen. A protely plasma activity was evident. MPO content significantly increased as did levels of interleukines. Treatment with the PAF inhibitor partly, though not fully, restored the changes caused by I/R.


PAF seems involved in the release of cytokines and consumption of protease inhibitors following intestinal I/R and the associated impairment of intestinal barrier integrity. Treatment with a PAF antagonist was effective in restoring changes caused by I/R, though not reaching normal levels.

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Andersson, R., Sun, Z., Wang, X. et al. Intestinal ischemia and reperfusion: beneficial effects of a platelet activating factor antagonist. Crit Care 3 (Suppl 1), P085 (2000).

Download citation

  • Published:

  • DOI: